News | January 17, 2026
Miach Orthopaedics’ BEAR implant gains FDA label claim for reduced arthritis risk
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Subscribe To Our Newsletter & Stay Updated
